2025 SE／BTA／BAETS声明：GLP-1激动剂与甲状腺癌的关系

Funding

The authors received no specific funding for this work.

# Conflicts of Interest

The authors declare no conflicts of interest.

# Data Availability Statement

Data sharing is not applicable to this article, as no data sets were generated or analysed during the current study.

References

1. J. P. H. Wilding, R. L. Batterham, S. Calanna, et al., "Once-Weekly Semaglutide in Adults With Overweight or Obesity," New England Journal of Medicine 384, no. 11 (March 2021): 989-1002.

2. D. K. McGuire, N. Marx, S. L. Mulvagh, et al., "Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes," New England Journal of Medicine 392, no. 20 (May 2025): 2001-2012.

3. S. P. Marso, G. H. Daniels, K. Brown-Frandsen, et al., "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes," New England Journal of Medicine 375, no. 4 (July 2016): 311-322.

4. P. N. Newsome, K. Buchholtz, K. Cusi, et al., "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis," New England Journal of Medicine 384, no. 12 (March 2021): 1133-1124.

5. J. H. Watanabe, J. Kwon, B. Nan, and A. Reikes, "Trends in Glucagon-Like Peptide 1 Receptor Agonist Use, 2014 to 2022," Journal of the American Pharmacists Association 64, no. 1 (January 2024): 133-138.

6. E. Mahase, "GLP-1 Agonists: US Sees 700% Increase Over Four Years in Number of Patients Without Diabetes Starting Treatment," BMJ 386 (July 2024): q1645.

7. L. W. Madsen, J. A. Knauf, C. Gotfredsen, et al., "GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and Not Associated With RET Activation," Endocrinology 153, no. 3 (March 2012): 1538-1547.

8. L. Bjerre Knudsen, L. W. Madsen, S. Andersen, et al., "Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation," Endocrinology 151, no. 4 (April 2010): 1473-1486.

9. "Highlights of Prescribing Information: OZEMPIC (Semaglutide) Injection, for Subcutaneous Use," US Food and Drug Administration, 2023, https://www.accessdata.fda.gov/drugsatfdaocs/label/2023/209637s020s021lbl.pdf.

10. M. A. Bethel, R. A. Patel, V. P. Thompson, et al., "Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)," Diabetes Care 42, no 6 (June 2019): 1075-1080.

11. L. Hegedüs, S. I. Sherman, R. M. Tuttle, et al., "No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial," Diabetes Care 41, no. 3 (March 2018): 620-622.

12. T. J. Rosol, "On-Target Effects of GLP-1 Receptor Agonists on Thyroid C-Cells and Mice," Toxicologic Pathology 41, no. 2 (February 2013): 303-309.

13. J. L. Vahle, R. A. Byrd, J. L. Blackbourne, et al., "Effects of Du-laglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys," Endocrinology 156, no. 7 (July 2015): 2409-2416.

14. G. Mali, V. Ahuja, and K. Dubey, "Glucagon-Like Peptide-1 Analogues and Thyroid Cancer: An Analysis of Cases Reported in the European Pharmacovigiance Database," Journal of Clinical Pharmacy and Therapeutics 46, no. 1 (February 2021): 99-105.

15. L. Duchemin, A. Morice, P. M. Morice, et al., "Risk of Thyroid Cancer Related to Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review With Meta-Analysis of Harms of Randomized Controlled Trials," Diabetes, Obesity and Metabolism 27, no. 8 (August 2025): 4607-4610.

16. W. Hu, R. Song, R. Cheng, et al., "Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: A Meta-Analysis of Randomized Controlled Trials," Frontiers in Endocrinology (Lausanne) 13 (July 2022): 927859.

17. T. Wu, Y. Zhang, Y. Shi, et al., "Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database," Clinical Drug Investigation 42, no. 11 (November 2022): 965-975.

18. J. Bezin, A. Gouverneur, M. Pénichon, et al., "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer," Diabetes Care 46, no. 2 (February 2023): 384-390.

19. G. A. Silverii, M. Monami, M. Gallo, et al., "Glucagon-Like Peptide-1 Receptor Agonists and Risk of Thyroid Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials," Diabetes, Obesity and Metabolism 26, no. 3 (March 2024): 891-900.

20. J. P. Brito, J. Herrin, K. S. Swarna, et al., "GLP-1RA Use and Thyroid Cancer Risk," JAMA Otolaryngology-Head & Neck Surgery 151, no. 3 (March 2025): 243.

21. B. Pasternak, V. Wintzell, A. Hviid, et al., "Glucagon-Like Peptide 1 Receptor Agonist Use and Risk of Thyroid Cancer: Scandinavian Cohort Study," BMJ 385 (April 2024): e078225.

22. S. M. Baxter, L. C. Lund, J. H. Andersen, et al., "Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study," Thyroid 35, no. 1 (January 2025): 69–78.

23. C. Alves, F. Batel-Marques, and A. F. Macedo, "A Meta-Analysis of Serious Adverse Events Reported With Exenatide and Liraglutide: Acute Pancreatitis and Cancer," Diabetes Research and Clinical Practice 98, no. 2 (November 2012): 271-284.

24. L. Wang, R. Xu, D. C. Kaelber, and N. A. Berger, "Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Pa-ients With Type 2 Diabetes," JAMA Network Open 7, no. 7 (July 2024): e2421305.

25. D. R. Morales, F. Bu, B. Viernes, et al., "Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study," Diabetes Care 48, no. 8 (August 2025): 1386-1394.

26. S. Bea, H. Son, J. H. Bae, S. W. Cho, J. Y. Shin, and Y. M. Cho, "Risk of Thyroid Cancer Associated With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study," Diabetes, Obesity and Metabolism 26, no. 1 (January 2024): 108-117.

27. Y. Lu, H. Dai, H. Tang, et al., "Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes," Obesity (Silver Spring), ahead of print, August 21, 2025: 1-13, https://doi.org/10.1002/oby.24366.

28. M. Kim, S. C. Kim, J. Kim, and B. H. Kim, "Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients With Type 2 Diabetes Mellitus," Diabetes & Metabolism Journal 49, no. 1 (January 2025): 49-59.

29. A. Shin, S. Cho, D. Jang, et al., "Body Mass Index and Thyroid Cancer Risk: A Pooled Analysis of Half a Million Men and Women in the Asia Cohort Consortium," Thyroid 32, no. 3 (March 2022): 306-314.

30. A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, "Body-Mass Index and Incidence of Cancer: A Systematic Review and Meta-Analysis of Prospective Observational Studies," Lancet 371, no. 9612 (February 2008): 569-578.

31. "Meeting Highlights: Pharmacovigilance Risk Assessment Committee (PRAC), 23-26 October 2023," European Medicines Agency (EMA), Amsterdam, 2023, https://www.ema.europa.eu/en/news.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.

Appendix 1: GLP-1 Medication and Thyroid Cancer - Information for Patients.